Marleen Kok, MD, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the St. Gallen International Breast Cancer Conference, highlighting upcoming sessions on de-escalation of therapy in the efforts of personalized medicine, adjuvant treatment as well as the necessity of adjuvant immunotherapy following neoadjuvant immunotherapy. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.